Commodore Capital LP 13F: Quarter-over-Quarter Portfolio Changes
Commodore Capital LP reported a disclosed portfolio value of approximately $1.7 billion in its latest SEC Form 13F-HR filing for Q2 2026, down 2.9% quarter on quarter. Over the quarter, the fund initiated 5 new positions, bought more shares in 6 holdings, trimmed 9 holdings, and exited 8 positions.
Commodore Capital LP's top buy was a new stake in Tango Therapeutics INC (TNGX) , equal to 4.2% of the disclosed portfolio. Its top sell was Nuvalent INC (NUVL) . The fund sold 88.0% of its previously reported shares, reducing the position's portfolio weight by 4.2 percentage points.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| TANGO THERAPEUTICS INC | TNGX | 4.2% | History → |
| EDITAS MEDICINE INC | EDIT | 1.7% | Holders → |
| INFLARX NV | IFRX | 1.0% | Holders → |
| RESEARCH ALLIANCE CORP III | RACC | 0.3% | Holders → |
| VISTAGEN THERAPEUTICS INC | VTGN | 0.0% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| RELMADA THERAPEUTICS INC | RLMD | +0.3% | +124.8% | Holders → |
| AVALO THERAPEUTICS INC | AVTX | +0.7% | +110.8% | Holders → |
| EYEPOINT INC | EYPT | +1.8% | +62.8% | History → |
| ASSEMBLY BIOSCIENCES INC | ASMB | +0.7% | +41.5% | Holders → |
| AN2 THERAPEUTICS INC | ANTX | +0.4% | +25.7% | Holders → |
| COGENT BIOSCIENCES INC | COGT | +0.6% | +5.6% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| NUVALENT INC | NUVL | -4.2% | 88.0% | Holders → |
| KYMERA THERAPEUTICS INC | KYMR | -1.9% | 66.7% | Holders → |
| SPYRE THERAPEUTICS INC | SYRE | -1.1% | 55.7% | History → |
| CELLDEX THERAPEUTICS INC NEW | CLDX | -2.0% | 49.9% | Holders → |
| SAB BIOTHERAPEUTICS INC | SABS | -0.3% | 34.8% | Holders → |
| RELAY THERAPEUTICS INC | RLAY | 3.6% | 29.4% | History → |
| ALKERMES PLC | ALKS | 0.8% | 28.6% | History → |
| PHARVARIS N V | PHVS | -0.2% | 25.7% | Holders → |
| TYRA BIOSCIENCES INC | TYRA | -1.9% | 24.2% | Holders → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| ERASCA INC | ERAS | 3.0% |
| XENON PHARMACEUTICALS INC | XENE | 2.8% |
| NURIX THERAPEUTICS INC | NRIX | 2.0% |
| CORVUS PHARMACEUTICALS INC | CRVS | 1.9% |
| SOLENO THERAPEUTICS INC | SLNO | 1.3% |
| OCULAR THERAPEUTIX INC | OCUL | 1.3% |
| PALISADE BIO INC | PALI | 0.7% |
| KARYOPHARM THERAPEUTICS INC | KPTI | 0.6% |
Net Portfolio Value ChangeQ2 2026
- $1.7BPrior quarter
- $1.7BCurrent quarter
- $-0.0BNet delta
- -2.9%% change
Methodology & FAQ
How Commodore Capital LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Commodore Capital LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Commodore Capital LP buy in Q2 2026?
In Q2 2026, Commodore Capital LP initiated 5 new positions (TANGO THERAPEUTICS INC (TNGX), EDITAS MEDICINE INC (EDIT), INFLARX NV (IFRX), RESEARCH ALLIANCE CORP III (RACC), VISTAGEN THERAPEUTICS INC (VTGN)); bought more shares of RELMADA THERAPEUTICS INC (RLMD), AVALO THERAPEUTICS INC (AVTX), EYEPOINT INC (EYPT), ASSEMBLY BIOSCIENCES INC (ASMB), AN2 THERAPEUTICS INC (ANTX) (the largest 5 of 6 adds).
What stocks did Commodore Capital LP sell in Q2 2026?
In Q2 2026, Commodore Capital LP fully sold 8 positions (ERASCA INC (ERAS), XENON PHARMACEUTICALS INC (XENE), NURIX THERAPEUTICS INC (NRIX), CORVUS PHARMACEUTICALS INC (CRVS), SOLENO THERAPEUTICS INC (SLNO), OCULAR THERAPEUTIX INC (OCUL), PALISADE BIO INC (PALI), KARYOPHARM THERAPEUTICS INC (KPTI)); reduced holdings in NUVALENT INC (NUVL), KYMERA THERAPEUTICS INC (KYMR), SPYRE THERAPEUTICS INC (SYRE), CELLDEX THERAPEUTICS INC NEW (CLDX), SAB BIOTHERAPEUTICS INC (SABS) (the largest 5 of 9 reductions).
Which positions did Commodore Capital LP initiate in Q2 2026?
Commodore Capital LP established 5 new positions in Q2 2026: TANGO THERAPEUTICS INC (TNGX, 4.2%), EDITAS MEDICINE INC (EDIT, 1.7%), INFLARX NV (IFRX, 1.0%), RESEARCH ALLIANCE CORP III (RACC, 0.3%), VISTAGEN THERAPEUTICS INC (VTGN, 0.0%).
Which existing positions saw the largest allocation increases for Commodore Capital LP in Q2 2026?
Of 6 existing positions with share-count increases in Q2 2026, the largest were: RELMADA THERAPEUTICS INC (RLMD, +0.3% weight, +124.8% shares), AVALO THERAPEUTICS INC (AVTX, +0.7% weight, +110.8% shares), EYEPOINT INC (EYPT, +1.8% weight, +62.8% shares), ASSEMBLY BIOSCIENCES INC (ASMB, +0.7% weight, +41.5% shares), AN2 THERAPEUTICS INC (ANTX, +0.4% weight, +25.7% shares), COGENT BIOSCIENCES INC (COGT, +0.6% weight, +5.6% shares).
Which positions did Commodore Capital LP fully exit in Q2 2026?
Commodore Capital LP fully exited 8 positions in Q2 2026: ERASCA INC (ERAS, last-reported weight 3.0%), XENON PHARMACEUTICALS INC (XENE, last-reported weight 2.8%), NURIX THERAPEUTICS INC (NRIX, last-reported weight 2.0%), CORVUS PHARMACEUTICALS INC (CRVS, last-reported weight 1.9%), SOLENO THERAPEUTICS INC (SLNO, last-reported weight 1.3%), OCULAR THERAPEUTIX INC (OCUL, last-reported weight 1.3%), PALISADE BIO INC (PALI, last-reported weight 0.7%), KARYOPHARM THERAPEUTICS INC (KPTI, last-reported weight 0.6%).
Which existing positions saw the largest allocation reductions for Commodore Capital LP in Q2 2026?
Of 9 existing positions with share-count reductions in Q2 2026, the largest were: NUVALENT INC (NUVL, -4.2% weight, -88.0% shares), KYMERA THERAPEUTICS INC (KYMR, -1.9% weight, -66.7% shares), SPYRE THERAPEUTICS INC (SYRE, -1.1% weight, -55.7% shares), CELLDEX THERAPEUTICS INC NEW (CLDX, -2.0% weight, -49.9% shares), SAB BIOTHERAPEUTICS INC (SABS, -0.3% weight, -34.8% shares), RELAY THERAPEUTICS INC (RLAY, 3.6% weight, -29.4% shares), ALKERMES PLC (ALKS, 0.8% weight, -28.6% shares), PHARVARIS N V (PHVS, -0.2% weight, -25.7% shares), TYRA BIOSCIENCES INC (TYRA, -1.9% weight, -24.2% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.